BIOMAT Database Logo BIOMAT Database Logo

Clinical relevance of BCL2, BCL6, and MYC rearrangements in diffuse large B-cell lymphoma. 1998

M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Departments of Pathology and Medical Statistics, Leiden University Medical Center, Leiden, The Netherlands.

Diffuse large B-cell lymphoma (DLCL) is characterized by a marked degree of morphologic and clinical heterogeneity. We studied 156 patients with de novo DLCL for rearrangements of the BCL2, BCL6, and MYC oncogenes by Southern blot analysis and BCL2 protein expression. We related these data to the primary site of presentation, disease stage, and other clinical risk factors. Structural alterations of BCL2, BCL6, and MYC were detected in 25 of 156, 36 of 116, and 10 of 151 patients, respectively. Three cases showed a combination of BCL2 and BCL6 rearrangements, and two cases had a combination of BCL6 and MYC rearrangements. BCL2 rearrangement was found more often in extensive (39%) and primary nodal (17%) lymphomas than in extranodal cases (4%) (P = .003). BCL2 rearrangement was present in none of 40 patients with stage I disease, but in 22% of patients with stage II to IV (P = .006). The presence of BCL2 rearrangements did not significantly affect overall survival (OS) or disease-free survival (DFS). In contrast, high BCL2 protein expression adversely affected both OS (P = .008) and DFS (P = .01). BCL2 protein expression was poorly correlated with BCL2 rearrangement: only 52% of BCL2-rearranged lymphomas and 37% of BCL2-unrearranged cases had high BCL2 protein expression. Rearrangement of BCL6 was found more often in patients with extranodal (36%) and extensive (39%) presentation versus primary nodal disease (28%). No significant correlation was found with disease stage, lymphadenopathy, or bone marrow involvement. DFS and OS were not influenced by BCL6 rearrangements. MYC rearrangements were found in 16% of primary extranodal lymphomas, versus 2% of primary nodal cases (P = .02). In particular, gastrointestinal (GI) lymphomas (5 of 18 cases, 28%) were affected by MYC rearrangements. The distinct biologic behavior of these extranodal lymphomas was reflected by a high complete remission (CR) rate: 7 of 10 patients with MYC rearrangement attained complete remission and 6 responders remained alive for more than 4 years, resulting in a trend for better DFS (P = .07). These data show the complex nature of molecular events in DLCL, which is a reflection of the morphologic and clinical heterogeneity of these lymphomas. However, thus far, these genetic rearrangements fail as prognostic markers.

UI MeSH Term Description Entries
D007143 Immunoglobulin Heavy Chains The largest of polypeptide chains comprising immunoglobulins. They contain 450 to 600 amino acid residues per chain, and have molecular weights of 51-72 kDa. Immunoglobulins, Heavy-Chain,Heavy-Chain Immunoglobulins,Ig Heavy Chains,Immunoglobulin Heavy Chain,Immunoglobulin Heavy Chain Subgroup VH-I,Immunoglobulin Heavy Chain Subgroup VH-III,Heavy Chain Immunoglobulins,Heavy Chain, Immunoglobulin,Heavy Chains, Ig,Heavy Chains, Immunoglobulin,Immunoglobulin Heavy Chain Subgroup VH I,Immunoglobulin Heavy Chain Subgroup VH III,Immunoglobulins, Heavy Chain
D009363 Neoplasm Proteins Proteins whose abnormal expression (gain or loss) are associated with the development, growth, or progression of NEOPLASMS. Some neoplasm proteins are tumor antigens (ANTIGENS, NEOPLASM), i.e. they induce an immune reaction to their tumor. Many neoplasm proteins have been characterized and are used as tumor markers (BIOMARKERS, TUMOR) when they are detectable in cells and body fluids as monitors for the presence or growth of tumors. Abnormal expression of ONCOGENE PROTEINS is involved in neoplastic transformation, whereas the loss of expression of TUMOR SUPPRESSOR PROTEINS is involved with the loss of growth control and progression of the neoplasm. Proteins, Neoplasm
D009426 Netherlands Country located in EUROPE. It is bordered by the NORTH SEA, BELGIUM, and GERMANY. Constituent areas are Aruba, Curacao, and Sint Maarten, formerly included in the NETHERLANDS ANTILLES. Holland,Kingdom of the Netherlands
D009857 Oncogenes Genes whose gain-of-function alterations lead to NEOPLASTIC CELL TRANSFORMATION. They include, for example, genes for activators or stimulators of CELL PROLIFERATION such as growth factors, growth factor receptors, protein kinases, signal transducers, nuclear phosphoproteins, and transcription factors. A prefix of "v-" before oncogene symbols indicates oncogenes captured and transmitted by RETROVIRUSES; the prefix "c-" before the gene symbol of an oncogene indicates it is the cellular homolog (PROTO-ONCOGENES) of a v-oncogene. Transforming Genes,Oncogene,Transforming Gene,Gene, Transforming,Genes, Transforming
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011518 Proto-Oncogene Proteins Products of proto-oncogenes. Normally they do not have oncogenic or transforming properties, but are involved in the regulation or differentiation of cell growth. They often have protein kinase activity. Cellular Proto-Oncogene Proteins,c-onc Proteins,Proto Oncogene Proteins, Cellular,Proto-Oncogene Products, Cellular,Cellular Proto Oncogene Proteins,Cellular Proto-Oncogene Products,Proto Oncogene Products, Cellular,Proto Oncogene Proteins,Proto-Oncogene Proteins, Cellular,c onc Proteins
D012074 Remission Induction Therapeutic act or process that initiates a response to a complete or partial remission level. Induction of Remission,Induction, Remission,Inductions, Remission,Remission Inductions
D004252 DNA Mutational Analysis Biochemical identification of mutational changes in a nucleotide sequence. Mutational Analysis, DNA,Analysis, DNA Mutational,Analyses, DNA Mutational,DNA Mutational Analyses,Mutational Analyses, DNA
D004268 DNA-Binding Proteins Proteins which bind to DNA. The family includes proteins which bind to both double- and single-stranded DNA and also includes specific DNA binding proteins in serum which can be used as markers for malignant diseases. DNA Helix Destabilizing Proteins,DNA-Binding Protein,Single-Stranded DNA Binding Proteins,DNA Binding Protein,DNA Single-Stranded Binding Protein,SS DNA BP,Single-Stranded DNA-Binding Protein,Binding Protein, DNA,DNA Binding Proteins,DNA Single Stranded Binding Protein,DNA-Binding Protein, Single-Stranded,Protein, DNA-Binding,Single Stranded DNA Binding Protein,Single Stranded DNA Binding Proteins
D004273 DNA, Neoplasm DNA present in neoplastic tissue. Neoplasm DNA

Related Publications

M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Coexistent rearrangements of c-MYC, BCL2, and BCL6 genes in a diffuse large B-cell lymphoma.
January 2004, International journal of hematology,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
High-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements with diffuse large B-cell lymphoma morphology.
May 2018, Blood,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
[The incidence of high-grade B-cell lymphoma with MYC and BCL2 and/or BCL6 rearrangements in diffuse large B-cell lymphoma].
February 2021, Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
MYC, BCL2, and BCL6 rearrangements in primary central nervous system lymphoma of large B cell type.
January 2019, Annals of hematology,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Primary cutaneous diffuse large B-cell lymphoma, leg type with MYC/BCL2/BCL6 overexpression.
February 2022, EJHaem,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Copy Number Alteration and Mutational Profile of High-Grade B-Cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements, Diffuse Large B-Cell Lymphoma with MYC-Rearrangement, and Diffuse Large B-Cell Lymphoma with MYC-Cluster Amplification.
November 2022, Cancers,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Extra copies of MYC, BCL2, and BCL6 and outcome in patients with diffuse large B-cell lymphoma.
July 2020, Blood advances,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
Interpreting MYC and BCL2 in diffuse large B-cell lymphoma.
October 2013, Leukemia & lymphoma,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma.
March 2013, Blood,
M H Kramer, and J Hermans, and E Wijburg, and K Philippo, and E Geelen, and J H van Krieken, and D de Jong, and E Maartense, and E Schuuring, and P M Kluin
BCL2 and BCL6 atypical/unbalanced gene rearrangements in diffuse large B-cell lymphoma are indicators of an aggressive clinical course.
October 2021, Journal of clinical pathology,
Copied contents to your clipboard!